

SUBSTANTIAL SHAREHOLDERS

So far as our Directors are aware, immediately following the completion of the [REDACTED] and the Conversion of Unlisted Shares into H Shares (assuming the [REDACTED] is not exercised), the following persons will have interests and/or short positions (as applicable) in the Shares or underlying Shares of our Company, which would be required to be disclosed to us and the Stock Exchange pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or will be, directly or indirectly, entitled to exercise, or control the exercise of, 10% or more of the voting power at any general meeting of our Company:

LONG POSITIONS IN THE SHARES OF OUR COMPANY

Name	Nature of Interest	Shares interested in as of the Latest Practicable Date		Shares interested in immediately following the completion of the [REDACTED] and the Conversion of Unlisted Shares into H Shares (assuming the [REDACTED] is not exercised)		
		Number and description	% of shareholding in the total issued share capital	Number and description	% of shareholding in the Unlisted Shares/H Shares ⁽¹⁾	% of shareholding in the total issued share capital ⁽¹⁾
PAG Highlander ⁽²⁾ . .	Beneficial owner	299,896,978 Unlisted Shares	44.62%	[149,948,489] Unlisted Shares [149,948,489] H Shares	[REDACTED]% [REDACTED]% [REDACTED]%	[REDACTED]% [REDACTED]% [REDACTED]%
Hisun Pharmaceutical ⁽³⁾ . .	Beneficial owner	266,250,000 Unlisted Shares	39.62%	[133,125,000] Unlisted Shares [133,125,000] H Shares	[REDACTED]% [REDACTED]% [REDACTED]%	[REDACTED]% [REDACTED]% [REDACTED]%
Cliff ⁽⁴⁾	Beneficial owner	31,208,791 Unlisted Shares	4.64%	[31,208,791] H Shares	[REDACTED]%	[REDACTED]%
Shanghai Pinzhan ⁽⁵⁾ . .	Beneficial owner	30,803,571 Unlisted Shares	4.58%	[30,803,571] H Shares	[REDACTED]%	[REDACTED]%

Notes:

- (1) The calculation is based on the total number of [283,073,489] Unlisted Shares and [REDACTED] H Shares in issue immediately upon completion of the [REDACTED] and the Conversion of Unlisted Shares into H Shares (assuming the [REDACTED] is not exercised). Unlisted Shares and H Shares are both ordinary Shares of the Company. For details, see “Share Capital — Shares of Our Company.”
- (2) PAG Highlander is a company established under the laws of Hong Kong, which is wholly owned by PAG Highlander II (Cayman) Limited. PAG Highlander II (Cayman) Limited is wholly owned by PAG Highlander I (Cayman) Limited. PAG Highlander I (Cayman) Limited is owned as to 90.12% and 9.88% by PAGAC III Highlander (Cayman) Limited and PAGGC I Highlander (Cayman) Limited, respectively. PAGAC III Highlander (Cayman) Limited is wholly owned by PAG Asia III LP. PAG Asia Capital GP III Limited is the general partner of PAG Asia III LP. PAG Asia Capital GP III Limited is wholly owned by PAG Capital Limited. PAG Capital Limited is wholly owned by Pacific Alliance Group Limited. Pacific Alliance Group Limited is wholly owned by PAG. Mr. Shan Weijian holds approximately 34.93% of the voting power in PAG.

SUBSTANTIAL SHAREHOLDERS

Therefore, each of PAG Highlander II (Cayman) Limited, PAG Highlander I (Cayman) Limited, PAGAC III Highlander (Cayman) Limited, PAG Asia III LP, PAG Asia Capital GP III Limited, PAG Capital Limited, Pacific Alliance Group Limited, PAG and Mr. Shan Weijian is deemed to be interested in the Shares held by PAG Highlander (HK) Limited under the SFO.

- (3) According to the public filing made by Hisun Pharmaceutical as a company whose shares are listed on the Shanghai Stock Exchange, Zhejiang Hisun, which was owned as to 79.86% by Taizhou Jiaojiang, is regarded as the controlling shareholder of Hisun Pharmaceutical, and therefore Taizhou Jiaojiang is deemed as the actual controller of Hisun Pharmaceutical. Please see “Relationship with Our Controlling Shareholders” for details. Therefore, each of Taizhou Jiaojiang and Zhejiang Hisun is deemed to be interested in the Shares held by Hisun Pharmaceutical under the SFO.
- (4) Cliff, a limited liability company incorporated under the laws of Singapore, is wholly owned by Enterprise Holding Pte Ltd and managed by GIC Special Investments Private Limited, which is in turn wholly owned by GIC Private Limited (“GIC”). As such, under the SFO, each of Enterprise Holding Pte Ltd, GIC Special Investments Private Limited and GIC is deemed to be interested in Shares held by Cliff.
- (5) Shanghai Pinzhan, our Employee Shareholding Platform and a limited partnership established in the PRC, is managed by its general partner, Shanghai Xinxi, which is in turn led by Dr. Zhu Wei, our chief medical officer. As of the Latest Practicable Date, Shanghai Ruishan is a limited partner of Shanghai Pinzhan holding approximately 34.18% partnership interest. The general partner of Shanghai Ruishan is Shanghai Xinxi. Save as Mr. Xiao Suining holding approximately 44.44% partnership interest in Shanghai Ruishan, no other limited partners held one-third or more partnership interest therein. As such, under the SFO, each of Shanghai Xinxi, Dr. Zhu Wei, Shanghai Ruishan and Mr. Xiao Suining is deemed to be interested in Shares held by Shanghai Pinzhan.

Save as otherwise disclosed herein, our Directors are not aware of any persons who will, immediately following the [REDACTED] and the Conversion of our Unlisted Shares into H Shares (assuming the [REDACTED] is not exercised), have any interests and/or short positions in the Shares or underlying Shares of our Company which would fall to be disclosed to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or will be, directly or indirectly, entitled to exercise, or control the exercise of, 10% or more of the voting power at any general meeting of our Company.